Pustulosis exantemática aguda generalizada inducida por omeprazol

Castillejo, Óscar Nantes; Urmeneta, José Manuel Zozaya; Peñalba, Ana; Virseda, José María Martínez-Peñuela

doi:10.1157/13119883

Cited by 13 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Figure 2a and Table 3 show highest incidence of EoE for adult or all age groups from small regional studies in Castilla-La-Mancha, Spain (11.9 per 100,000 person-years during 2015-2017), 16 and Cáceres, Spain (10.5 in 2014-2016), 18 followed by a nationwide study across Denmark (7.8 in 2016-2018), 14 and two regional studies from Olten County, Switzerland (7.4 in 2007-2009), 24 and north Denmark (7.1 in 2015-2017). 15 Lowest EoE incidence refers to nationwide studies in Denmark (1.9 in 2009-2012), 23 and The Netherlands (1.9 in 2012-2015), 20 a regional study from Navarra, Spain (2.1 in 2002-2008), 26 and two nationwide studies from The Netherlands (2.6 in 2015-2019), 13 and Sweden (2.8 in 2013-2015). 19 The meta-analysis- -93…”

Section: Incidence and Prevalence Of Eoe For Adults Across Europementioning

confidence: 99%

Incidence and prevalence of eosinophilic oesophagitis across Europe: A systematic review and meta‐analysis

Roberts,

Morrison‐Rees,

Thapar

et al. 2023

UEG Journal

View full text Add to dashboard Cite

BackgroundSeveral studies have reported large increases in the incidence of eosinophilic oesophagitis (EoE) in the last 20 years. We aimed to systematically review the incidence and prevalence of EoE, focused on all European countries.MethodsSystematic review and meta‐analysis up to 31 December 2022, based on PubMed, CINAHL and extensive hand searching of reference lists. Twenty‐five eligible studies were identified and included.ResultsFor both adults and children, the highest EoE incidence and prevalence have been reported from regional studies in Spain. EoE incidence for both adults and children was significantly lower (p < 0.001) in nationwide studies (meta‐analysis = 3.64 per 100,000 person‐years overall) compared with regional or centre‐based studies (7.16). EoE incidence and prevalence were significantly higher (p < 0.001) in adults than children. All studies that reported on longitudinal trends in EoE incidence showed increases over time, more markedly during more recent years. Larger increases in incidence tend to refer to regional rather than nationwide studies; from Spain, Switzerland and Denmark, both for paediatric and adult age groups. Increases in EoE incidence 100,000 person‐years were larger than for incidence per number of diagnostic endoscopies. The most frequently reported co‐morbidities in adults were rhinitis, followed by asthma, food allergy and gastroesophageal reflux disease, and in children, erosive oesophagitis, asthma, food allergy and rhinitis.ConclusionsThe incidence of EoE has increased in Europe over the last 30 years, exceeding increases in the volume of oesophago‐gastro‐duodenoscopies performed. The patchy and low incidence and prevalence of EoE generally in Europe and compared with North America, may reflect a lack of clinical awareness and research focus rather than a genuinely low incidence of EoE. A co‐ordinated Europe‐wide study that uses standardised methodology is urgently needed to provide a comprehensive picture of EoE incidence and prevalence across Europe.

show abstract

Section: Incidence and Prevalence Of Eoe For Adults Across Europementioning

confidence: 99%

Incidence and prevalence of eosinophilic oesophagitis across Europe: A systematic review and meta‐analysis

Roberts,

Morrison‐Rees,

Thapar

et al. 2023

UEG Journal

View full text Add to dashboard Cite

show abstract

“…All clinical features of delayed HSRs have been reported with PPI. 27 They can induce mild maculopapular eruption 71,72 fixed drug eruption (FDE) 71,73 but also severe generalized bullous FDE (GBFDE), 71 photosensitization with rabeprazole and esomeprazole, 74 symmetrical drug-induced flexural exanthema (SDRIFE), 47 DRESS, 71,75,76 acute generalized exanthematous pustulosis 71,77,78 and TEN. (Mopral® 10 mg capsule) and pantoprazole at 6.09% (Eupantol® 40 mg tablet).…”

Section: Clinical Featuresmentioning

confidence: 99%

Hypersensitivity reactions to proton pump inhibitors. An EAACI position paper

Bavbek,

Kepil Özdemir,

Bonadonna

et al. 2023

Allergy

View full text Add to dashboard Cite

Proton pump inhibitors (PPIs) are invaluable therapeutic options in a variety of dyspeptic diseases. In addition to their well‐known risk profile, PPI consumption is related to food and environmental allergies, dysbiosis, osteoporosis, as well as immediate and delayed hypersensitivity reactions (HSRs). The latter, although a rare event, around 1%–3%, due to the extraordinarily high rate of prescription and consumption of PPIs are related to a substantial risk. In this Position Paper, we provide clinicians with practical evidence‐based recommendations for the diagnosis and management of HSRs to PPIs. Furthermore, the unmet needs proposed in the document aim to stimulate more in‐depth investigations in the topic.

show abstract

“…[ 19 ] Some rarely incriminated drugs include terazosin hydrochloride, omeprazole, and sennoside [ Table 1 ]. [ 20 21 22 ]…”

Section: Aetiologymentioning

confidence: 99%

Acute generalised exanthematous pustulosis: An update

Das

Sarda³

et al. 2018

Indian J Dermatol

View full text Add to dashboard Cite

Acute generalised exanthematous pustulosis (AGEP) is a severe cutaneous adverse reaction and is attributed to drugs in more than 90% of cases. It is a rare disease, with an estimated incidence of 1–5 patients per million per year. The clinical manifestations characterised by the rapid development of sterile pustular lesions, fever and leucocytosis. Number of drugs has been reported to be associated with AGEP, most common being the antibiotics. Histopathologically there is intraepidermal pustules and papillary dermal oedema with neutrophilic and eosinophilic infiltrations. Systemic involvement can be present in more severe cases. Early diagnosis with withdrawal of the causative drug is the most important step in the management. Treatment includes supportive care, prevention of antibiotics and use of a potent topical steroid.

show abstract

Pustulosis exantemática aguda generalizada inducida por omeprazol

Cited by 13 publications

References 5 publications

Incidence and prevalence of eosinophilic oesophagitis across Europe: A systematic review and meta‐analysis

Incidence and prevalence of eosinophilic oesophagitis across Europe: A systematic review and meta‐analysis

Hypersensitivity reactions to proton pump inhibitors. An EAACI position paper

Acute generalised exanthematous pustulosis: An update

Contact Info

Product

Resources

About